Trial Name	Description
Window of Opportunity	Dr. Anthony Nichols A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment with BYL719.
RADIO	Dr. Sara Kuruvilla Randomized Trial Comparing Low-Dose Weekly to High-Dose Cisplatin Concurrent with Radiation for Locally Advanced Head and Neck Cancer.
LIBRETTO HN	Dr. E. Winquist A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naive, RET-Mutant Medullary Thyroid Cancer
TIPIT HN	Dr. Sara Kuruvilla Not Yet Open - Combined Checkpoint Co-blockade in Resectable Oral Cavity and Larynx Cancer – a Window of Opportunity Trial
Dab+Tram Thyroid	Dr. E. Winquist A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of dabrafenib plus trametinib in previously treated patients with locally advanced or metastatic, radio-active iodine refractory BRAFV600E mu
PRESERVE	Dr. David Palma Preservation of Swallowing in Resected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial.
CE.7	Dr. Melody Qu A Phase III Trial of Stereotactic Radiosurgery Compared with Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5-15 Brain Metastases.
HNC.2	Dr. Eric Winquist Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin.
ASPEN-03 HN	Dr. E. Winquist A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
HN.11 H&N	Dr. Danielle Macneil Not Yet Open - SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial.
eVOLVE-HNSCC	Dr. Sara Kuruvilla A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progress
5FAST HN	Dr. Chris Goodman Not Yet Open - "3-5 FrAction Stereotactic Body Radiation Therapy for Palliation of Head and Neck Squamous Cell Carcinoma: the FAST Phase II Randomized Trial"